Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors

被引:0
|
作者
Geoffrey Masuyer
Jonathan R. Davies
Kevin Moore
John A. Chaddock
K. Ravi Acharya
机构
[1] University of Bath,Department of Biology and Biochemistry
[2] Ipsen Bioinnovation Limited,Department of Biochemistry and Biophysics, Arrhenius Laboratories for Natural Sciences
[3] Stockholm University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The botulinum neurotoxin type D is one of seven highly potent toxins produced by Clostridium botulinum which inhibit neurotransmission at cholinergic nerve terminals. A functional fragment derived from the toxin, LHn, consisting of the catalytic and translocation domains, has been heralded as a platform for the development of targeted secretion inhibitors. These secretion inhibitors are aimed at retargeting the toxin towards a specific cell type to inhibit vesicular secretion. Here we report crystal structures of LHn from serotype D at 2.3?Å and that of SXN101959 at 3.1?Å resolution. SXN101959, a derivative that combines LHn from serotype D with a fragment of the growth hormone releasing hormone, has previously revealed promising results in inhibiting growth hormone release in pituitary somatotrophs. These structures offer for the first time insights into the translocation domain interaction with the catalytic domain in serotype D. Furthermore, structural information from small-angle X-ray scattering of LHn/D is compared among serotypes A, B and D. Taken together, these results demonstrate the robustness of the ‘LHn fold’ across serotypes and its use in engineering additional polypeptide components with added functionality. Our study demonstrates the suitability of botulinum neurotoxin and serotype D in particular, as a basis for engineering novel secretion inhibitors.
引用
收藏
相关论文
共 50 条
  • [1] Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
    Masuyer, Geoffrey
    Davies, Jonathan R.
    Moore, Kevin
    Chaddock, John A.
    Acharya, K. Ravi
    SCIENTIFIC REPORTS, 2015, 5
  • [2] Production and purification of Clostridium botulinum type C and D neurotoxin
    Gessler, F
    Böhnel, H
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1999, 24 (03): : 361 - 367
  • [3] Development of potent inhibitors of botulinum neurotoxin type B
    Anne, C
    Turcaud, S
    Quancard, J
    Teffo, F
    Meudal, H
    Fournié-Zaluski, MC
    Roques, BP
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (22) : 4648 - 4656
  • [4] CLOSTRIDIUM-BOTULINUM TYPE-D NEUROTOXIN - PURIFICATION AND DETECTION
    DEJONGH, KS
    SCHWARTZKOFF, CL
    HOWDEN, MEH
    TOXICON, 1989, 27 (02) : 221 - 228
  • [5] Analysis of the botulinum neurotoxin type F gene clusters in proteolytic and nonproteolytic Clostridium botulinum and Clostridium barati
    East, AK
    Bhandari, M
    Hielm, S
    Collins, MD
    CURRENT MICROBIOLOGY, 1998, 37 (04) : 262 - 268
  • [6] Analysis of the Botulinum Neurotoxin Type F Gene Clusters in Proteolytic and Nonproteolytic Clostridium botulinum and Clostridium barati
    Alison K. East
    Manju Bhandari
    Sebastian Hielm
    Matthew D. Collins
    Current Microbiology, 1998, 37 : 262 - 268
  • [7] Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B
    Swaminathan, S
    Eswaramoorthy, S
    NATURE STRUCTURAL BIOLOGY, 2000, 7 (08) : 693 - 699
  • [8] Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B
    Subramanyam Swaminathan
    Subramaniam Eswaramoorthy
    Nature Structural Biology, 2000, 7 : 693 - 699
  • [9] Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains
    Rao, Sphoorthy
    Starr, Renate L.
    Morris, Melissa G.
    Lin, Wei-Jen
    FOODBORNE PATHOGENS AND DISEASE, 2007, 4 (02) : 201 - 207
  • [10] Characterization of neurotoxin mutants in Clostridium botulinum type A.
    Johnson, EA
    Lin, WJ
    Zhou, YT
    Bradshaw, M
    CLINICAL INFECTIOUS DISEASES, 1997, 25 : S168 - S170